PAVmed Stock Discussion

$PAVmed (PAVM.US)$ $Lucid Diagnostics (LUCD.US)$
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Monday, 23rd December at 8:01 am
NEW YORK, Dec. 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced that it had received written notification from the Listing Qualifications Depart...

$Lucid Diagnostics (LUCD.US)$ $PAVmed (PAVM.US)$
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication
Wednesday, 11th December at 8:01 am
Study demonstrates outstanding clinical utility including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard esophageal precancer testing
NEW YORK, Dec. 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or...

$PAVmed (PAVM.US)$ Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication
2 MINUTES AGO, 8:01 AM EST
VIA PR NEWSWIRE
Study demonstrates outstanding clinical utility including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard esophageal precancer testing

$PAVmed (PAVM.US)$ $Lucid Diagnostics (LUCD.US)$ Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard Esophageal DNA Test
PR Newswire· 2 mins ago
NEW YORK, Nov. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.(Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has submitted its complete clinical evidence package for its Eso...

$PAVmed (PAVM.US)$
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care
PAVmed's subsidiary, Veris Health, has been awarded a $1.8 million grant from the National Institute on Minority Health and Health Disparities (NIMHD), part of the National Institutes of Health (NIH). The two-year grant will fund research to optimize and validate the Veris Cancer Care Platform for medically underserved cancer patients, in partnership with an academic cancer center.
The ...

$PAVmed (PAVM.US)$ Reuters· just
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million Nih Grant to Enhance Cancer Care

$Advent Technologies (ADN.US)$ $flyExclusive (FLYX.US)$ $Banzai International (BNZI.US)$ $Anebulo Pharmaceuticals (ANEB.US)$ $Jin Medical International (ZJYL.US)$ $ShiftPixy (PIXY.US)$ $Gaxos.ai (GXAI.US)$   $Scilex Holding (SCLX.US)$ $PAVmed (PAVM.US)$
📊⚡️📊

Follow Our Official Telegram Channel tynkrlab
$Dow Jones Industrial Average (.DJI.US)$ rose by 0.59% to a new record high, closing at 41,211.12. In contrast, the $S&P 500 Index (.SPX.US)$ fell by 1.39%, and the $Nasdaq Composite Index (.IXIC.US)$ dropped by 2.76%. Tech stocks faced significant pressure, contributing to the mixed market performance.
Key Drivers
1. Strong Performers: $UnitedHealth (UNH.US)$, $Johnson & Johnson (JNJ.US)$, and $Cisco (CSCO.US)$ l...

$PAVmed (PAVM.US)$ Welcome to meme family.

$PAVmed (PAVM.US)$ PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program With the Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute